Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
- NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that it has reached agreement with the U.S. Food and Drug Administration FDA under a Special Protocol Assessment SPA for its planned Phase III clinical trial...
- Research articles 2008-04-22
- Breast Cancer Diagnostic Markers Licensed by Perlegen in Agreement with University of Cambridge and Cancer Research Technology
- DNA from More Than 50,000 Women Analyzed in Collaborative Research
- Research articles 2007-10-16
- Matritech and Mitsubishi Kagaku Medical Finalize Agreement to Develop NMP66 Blood Test for Breast Cancer
- Business Editors/Health/Medical Writers
- Research articles 2003-03-06
- Fischer Imaging Corp. and CADx Medical Systems Sign Development Agreement; - Will Provide Versatile, Cost-Effective Tool for Breast Cancer Detection -.
- DENVER and LAVAL, Quebec, Nov 22, 2000 DENVER and LAVAL, Quebec, Nov 22, 2000
- Research articles 2000-11-27
Additional Resources
- Sectra AB and R2 Technology Inc sign partnership agreement within breast cancer detection
- NORDIC BUSINESS REPORT-19 January 2004-Sectra AB and R2 Technology Inc sign partnership agreement within breast cancer detectionC1994-2004 M2 COMMUNICATIONS LTD http://www.m2.com The Swedish high-tech company Sectra AB said on Monday (19 January) that it had signed a partnership agreement with the US medical IT company R2 Technology Inc. ...
- Research articles 2004-01-19
- GE Healthcare and Confirma form alliance to deliver MRI computer-aided detection for breast cancer
- Confirma, a provider of computer-aided-detection CAD for breast magnetic resonance imaging MRI, and GE Healthcare have signed a strategic alliance to bring MRI technologies for breast cancer detection to healthcare providers. Under the agreement, GE will distribute Confirma's CADstreamTM software to its MR customers worldwide. CADstream technology enhances the clinical...
- Research articles 2004-08-01
- Early detection breast cancer patent licensed by Samaritan.(Brief Article)
- Samaritan Research Laboratories of Samaritan Pharmaceuticals, Inc. (Washington, DC; 702-735-7001), announced that Georgetown University (Wash-ington, DC) has granted Samaritan an Exclusive Worldwide Licensing Agreement to champion a breast cancer patent that can be used as a tool to improve the detection, diagnosis, prognosis, preven-tion and...
- Research articles 2001-07-01
- BG Medicine Forms Research Collaboration with M.D. Anderson Cancer Center to Discover Serum Biomarkers for Breast Cancer Treatment Response
- WALTHAM, Mass. -- BG Medicine announced today that it has entered into a research collaboration with The University of Texas M. D. Anderson Cancer Center aimed at improving the treatment of breast cancer. Under this agreement, BG Medicine will apply its biomarker discovery technology to the analysis of clinical samples...
- Research articles 2007-05-09
- Celera and LabCorp® Announce Licensing Agreement to Commercialize Breast Cancer Testing Assays
- ROCKVILLE, Md. & BURLINGTON, N.C. -- Celera (NYSE:CRA), an Applera Corporation business, and Laboratory Corporation of America([R]) Holdings (LabCorp([R])) (NYSE:LH), a national leader in esoteric and oncology testing, today announced that they have signed an agreement granting LabCorp a license to Celera's breast cancer metastasis and estrogen/progesterone receptor discoveries. The...
- Research articles 2007-04-25
- GE Healthcare and Confirma Form Alliance to Deliver MRI Computer-Aided Detection — CAD — for Breast Cancer
- KIRKLAND, Wash. & WAUKESHA, Wis. -- Confirma, the market leader for computer-aided-detection CAD for breast magnetic resonance imaging MRI, and GE Healthcare announced today that the companies have signed a strategic alliance to bring the industry's leading MRI technologies for breast cancer detection to healthcare providers. Under the agreement, GE...
- Research articles 2004-07-02
- Matritech Signs Term-Sheet for First Partnership to Provide Blood Test for Breast Cancer
- Business Editors and Health/Medical Writers BIOWIRE2K NEWTON, Mass.--BW HealthWire--Oct. 11, 2002 Matritech Inc. (NASDAQ: NMPS) has reached an agreement in principle for its NMP66TM breast cancer test with Mitsubishi Kagaku Medical Inc., a division of Mitsubishi Chemical, a $13 billion diversified international corporation that includes one of...
- Research articles 2002-10-11
- Miraculins Announces Start of Breast Cancer Study.
- WINNIPEG, MANITOBA, Jan 11, 2005 CCNMatthews via COMTEX Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company engaged in the discovery and development of products for select cancers, is pleased to announce the launch of its breast cancer study program with the initiation of an agreement...
- Research articles 2005-01-11
- Genentech and DAKO Announce Collaboration On HER2 Diagnostic Kit in Breast Cancer
- --BW HealthWire--March 2, 1998--Genentech, Inc. (NYSE:GNE) and DAKO A/S today announced an agreement under which DAKO will develop an in vitro diagnostic kit to be used to screen breast cancer patients for overexpression of a growth factor receptor known as HER2 and potential eligibility for treatment with Genentech's humanized monoclonal...
- Research articles 1998-03-02
- SRI International and Taiho Pharmaceutical Collaborate to Develop New Approach to Breast Cancer
- MENLO PARK, Calif.--BUSINESS WIRE--Oct. 14, 1996--SRI International and Taiho Pharmaceutical Co., Ltd. Tokyo, today announced a research agreement to develop a new chemotherapy approach to breast cancer.
- Research articles 1996-10-14
- Aurora Imaging Technology of United States Teams up with National Synchrotron Radiation Research Center of Taiwan to Tackle Scientific and Technological Issues on Breast Cancer
- NORTH ANDOVER, Mass. -- Aurora Imaging Technology Inc. is proud to announce a partnership with a preeminent National Laboratory of Taiwan, the National Synchrotron ...
- Research articles 2009-03-02
- Biosystems International Raises $ 4.6 Million Venture Capital for New Diagnostics in Cancer
- PARIS -- Biosystems International biotech leader in the development of monoclonal antibody based diagnostics for cancer, receives venture capital amounting to 3.5 million Euros ($4.6 million) from VC-funds managed by SGAM AI, a major Pharmaceutical Company in Central Eastern Europe, and private investors. The company will employ these funds to...
- Research articles 2008-10-29
- BayPoint Biosystems Acquires Exclusive Commercial Rights to Proteomic Patent Portfolio from the University of Texas M. D. Anderson Cancer Center
- HOUSTON -- BayPoint Biosystems Inc., a privately held personalized medicine company, announced today that it has entered into a technology licensing agreement with the University of Texas M. D. Anderson Cancer Center. Under the terms of the agreement, BayPoint obtains exclusive, worldwide commercial rights to certain proteomic technologies as well...
- Research articles 2008-03-27
- Affymetrix and IPSOGEN Collaborate to Develop and Market In-Vitro Diagnostic Cancer Tests
- SANTA CLARA, Calif. -- Affymetrix Inc. (Nasdaq: AFFX) and IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that they have signed a Powered by Affymetrix[TM] PbA agreement. With this agreement, IPSOGEN gains non-exclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic IVD...
- Research articles 2007-08-28
- Matritech and Bruker Daltonics Announce Partnership for Proteomics-Based Cancer Screening by Mass Spectrometry
- Business Editors & Health/Medical Writers NEWTON & BILLERICA, Mass.--BW HealthWire--May 20, 2002 Matritech Inc. (NASDAQ: NMPS) and Bruker Daltonics Inc. (NASDAQ: BDAL) announced today that they have formed a partnership to develop an automated mass spectrometer system that will allow clinical laboratories to efficiently perform Matritech's proteomics-based cancer...
- Research articles 2002-05-20
- TAMOXIFEN CITRATE.(cancer drug developed by Zeneca Pharmaceuticals and Roche Laboratories)
- TAMOXIFEN CITRATE-Zeneca Pharmaceuticals and Hoffmann-La Roche Inc.'s Roche Laboratories will co-promote Nolvadex tamoxifen citrate, a drug for the ... TAMOXIFEN CITRATE-Zeneca Pharmaceuticals and Hoffmann-La Roche Inc.'s Roche Laboratories will co-promote Nolvadex tamoxifen citrate, a drug for the prevention of breast cancer, in the US, pending...
- Research articles 1998-09-07
- << Previous
- page 1 of 1
- Next >>
Presented by American Express